Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma

Inclusion Criteria: 1. Age 18-75 years, male or female； 2. Performance status ≤ 2 ; 3. Nasopharyngeal cancer patients diagnosed by pathology (including histology or cytology) , of nasopharyngeal non-keratonic carcinoma (differentiated or undifferentiated, whether TNM staging); 4. Have at least one evaluable lesion (according to Recist1.1 criteria) 5. Expected survival ≥6 months. 6. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g/L, b. WBC ≥3×10\^9/L c. ANC≥1.5×10\^9/L, d. PLT ≥100×10\^9/L; (2) Biochemical examination must meet the following standards: a. BIL\<1.5 times the upper limit of normal value (ULN), b. ALT and AST\<2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\>60ml/min (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range. 7. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures. Exclusion Criteria: 1. Pregnant or lactating women 2. As determined by the investigators, there were severe comorbidities that could not tolerate or complete radiation therapy. 3. There are contraindications in MRI; 4. Second primary malignancy exists; 5. Patients with severe complications,such as hypertension, coronary heart disease,mental disease or patients who had any allergies before; 6. Received any other research in the past 4 weeks before enrollment.